Saffron 30mg 12 Months: Early AMD Visual Acuity +1.2 Lines, Macular Thickness +12% RCT
WELLNESS

Saffron 30mg 12 Months: Early AMD Visual Acuity +1.2 Lines, Macular Thickness +12% RCT

By Sophie · · British Journal of Ophthalmology 2025
KO | EN

Standardized saffron (Crocus sativus, affron) 30mg/day for 12 months improved best-corrected visual acuity (BCVA) by 1.2 lines, macular retinal thickness by 12%, contrast sensitivity by 28%, light adaptation by 22%, and daily visual function (NEI-VFQ-25) by 35% in 200 early age-related macular degeneration (AMD) patients, per a 2025 British Journal of Ophthalmology RCT. Natural first-line matrix validation for the era when 13% of Korean adults 50+ and 25% of those 70+ have AMD.

The study followed 200 early AMD patients (drusen + visual acuity decline) over 12 months in a randomized double-blind design. Saffron standardized extract affron 30mg/day (crocin 3.5%+ standardized) or placebo. Results: visual acuity +1.2 lines (0.7 → 0.85; placebo -0.3 lines), macular thickness +12% (drusen absorption signal), contrast sensitivity (Pelli-Robson) +28%, light adaptation time +22%, daily visual function +35%, multifocal ERG +18%. Side effects: GI discomfort 8%.

Saffron — RCT Revival of a 4,000-Year Persian Spice

What it is:

  • Crocus sativus flower stigmas (1kg requires 150,000 flowers — world’s most expensive spice)
  • Core actives: crocin, crocetin, safranal
  • 4,000-year Persian and Indian medical tradition
  • Australian affron (SaffronUp) and Iranian SaffroMood standardized extracts registered

Mechanisms:

  • Retinal photoreceptor (rod, cone) oxidative stress -38%
  • Retinal pigment epithelium (RPE) mitochondrial protection
  • Retinal microcirculation +25% (vasodilation)
  • Anti-VEGF action (neovascularization inhibition, AMD progression block)
  • BDNF and neurotrophic factor elevation

AMD — 13% of Korean 50+

AMD is the leading cause of blindness in those 65+. Drusen (waste deposits) accumulate in the macula → photoreceptor and RPE damage → central vision decline. Stages: early (drusen) → intermediate (visual decline) → late (dry/wet).

Korean statistics:

  • 50+: 13%, 70+: 25%
  • Family history, smoking, UV, high-fat diet, oxidative stress
  • 50%+ progress to visual acuity 0.5 or below within 5 years of diagnosis
  • Anti-VEGF injections (ranibizumab, aflibercept) standard but invasive

AREDS2 + Saffron Matrix — A New Era

The existing AREDS2 matrix (lutein 10mg + zeaxanthin 2mg + vitamin C 500mg + E 400IU + zinc 80mg + copper 2mg) verified -25% progression. The current RCT proposes adding saffron to the matrix. Anti-VEGF + antioxidant + microcirculation multi-target.

Synergy data:

  • Saffron + AREDS2: progression -42% (vs alone -25%)
  • Saffron + DHA 500mg: contrast sensitivity +35%
  • Saffron + bilberry 160mg: light adaptation +30%

affron 30mg/day — Critical Dose

The RCT used saffron standardized extract affron. Crocin 3.5%+ and safranal 0.3%+ standardized. Non-standardized saffron has highly variable active content. Regular spice-grade saffron (cooking) lacks sufficient concentration to reproduce RCT effects.

Matrix — DHA, Astaxanthin, Bilberry Synergy

Eye-vision 5-molecule matrix:

  • Saffron 30mg/day (retinal antioxidant + VEGF + microcirculation)
  • Lutein 10mg + Zeaxanthin 2mg (macular pigment density)
  • Astaxanthin 6mg/day (ciliary muscle + retinal ganglion)
  • DHA 500mg/day (photoreceptor membrane)
  • Bilberry 160mg/day (microcirculation + night vision)

Cautions

Safety matrix:

  • Pregnancy contraindicated (saffron uterine contraction risk, dangerous at 100mg+)
  • SSRI co-administration: physician evaluation (serotonin synergy)
  • Anticoagulant evaluation
  • GI sensitivity 8% (take after meals)
  • 12+ months cumulative evaluation, regular OCT tracking

Korean Market Status

Distribution:

  • Australian PharmacyXpress affron 30mg: 80,000-150,000 KRW per 60 caps
  • Iranian SaffroMood: 50,000-100,000 KRW
  • Substandard saffron-as-spice yields different effects
  • AMD diagnosed: ophthalmology collaboration + matrix evaluation

Global Saffron Medical Market

Europe: German BfArM saffron registered for adjunct depression treatment US: NIH 18+ AMD and depression RCTs ongoing Korea: AMD adjunct market in early formation post-2025

Spring 2026, the saffron affron 30mg/day RCT validating early AMD visual acuity +1.2 lines marks not just a spice but the starting point of a multi-target natural matrix targeting retinal anti-VEGF, microcirculation, and antioxidant pathways. Post-AMD diagnosis: anti-VEGF injection + saffron + AREDS2 multilayered adjunct era.